Investor mix
10 investors on record; lead investors include Highlight Capital, Shiyu, General Atlantic, IDG Capital; 3 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 3 | 30% |
| Private equity | 7 | 70% |
Developer of antibody-based therapeutics for cancer treatment
10 investors on record; lead investors include Highlight Capital, Shiyu, General Atlantic, IDG Capital; 3 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 3 | 30% |
| Private equity | 7 | 70% |